RxDoctor Payments Data

Cheryl White-Davis, PA

Medical · Williamsville, NYNPI 1922016138

Payments from drug & device makers

$5,662in general payments, 2019–2025

Across 142 payments — averaging $39.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • Johnson & Johnson$2K
  • Amgen$518
  • AbbVie$422
  • Incyte Corporation$308
  • Sun Pharmaceutical Industries Inc.$125
  • plus $305 from 8 others

What the payments were for

  • Consulting fees$2,96352%
  • Food & beverage$2,24640%
  • Education$4538%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,662 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$133,194
Medicare patients
438
Services billed
1,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab77$627,153
StelaraUstekinumab30$413,660
TremfyaGuselkumab28$365,086
Humira(Cf)Adalimumab25$170,972
Cosentyx Sensoready (2 Pens)Secukinumab17$118,381
Taltz AutoinjectorIxekizumab17$115,727
Dupixent PenDupilumab25$87,500
Adalimumab-Adaz(Cf) PenAdalimumab-Adaz18$23,111
Betamethasone Dipropionate207$9,917
Metronidazole65$8,200
Calcipotriene21$3,337
Clobetasol Propionate89$3,303
Mycophenolate Mofetil38$3,142
MethotrexateMethotrexate Sodium116$2,835
Fluorouracil46$2,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Tremfya$1,738$778,74658 claims
AbbVieHumira(Cf)$422$170,97225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.

Other medical in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →